Skip to content
LillyOncMed· @LillyOncMed · X·· 2 days agoScore60
Body

#ESMO2026 attendees: We invite you to explore real-world data on 3-month persistence and adherence to adjuvant abemaciclib in high-risk HR+, HER2- EBC: from ABSIDE-S. ePoster 1933eP View program details here: https://t.co/lJvrvDTCFD #BCSM #EBC https://t.co/GVUQhkPfo3

Heat 3 · 3 likes · 0 replies · 0 reposts

Source: LillyOncMed · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org